Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Somatic Variations in Cervical Cancers in Indian Patients

  • Poulami Das,

    Current address: Department of Molecular Biosciences, Centre for Infectious Disease, University of Texas, Austin, TX, United States of America

    Affiliation Mulherkar Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India

  • Akanksha Bansal,

    Affiliation Mulherkar Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India

  • Sudha Narayan Rao,

    Affiliation Genotypic Technology Pvt. Ltd., #259, Apoorva 4th Cross, 80 Ft Road, RMV II Stage, Bengaluru, 560094, India

  • Kedar Deodhar,

    Affiliation Department of Pathology, Tata Memorial Hospital, Parel, Mumbai, 400012, India

  • Umesh Mahantshetty,

    Affiliation Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, 400012, India

  • Shyam K. Shrivastava,

    Affiliation Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, 400012, India

  • Karthikeyan Sivaraman,

    Affiliation Dhitiomics Technologies Pvt. Ltd. #2/10, 5th Floor, 80 Feet Road, RMV 2nd Stage, Poojari Layout, Bengaluru, Karnataka, 560094, India

  • Rita Mulherkar

    Current address: A 103, Park Dew, Sector 20, Kharghar, Navi Mumbai, 410210, India

    Affiliation Mulherkar Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India

Somatic Variations in Cervical Cancers in Indian Patients

  • Poulami Das, 
  • Akanksha Bansal, 
  • Sudha Narayan Rao, 
  • Kedar Deodhar, 
  • Umesh Mahantshetty, 
  • Shyam K. Shrivastava, 
  • Karthikeyan Sivaraman, 
  • Rita Mulherkar


There are very few reports that describe the mutational landscape of cervical cancer, one of the leading cancers in Indian women. The aim of the present study was to investigate the somatic mutations that occur in cervical cancer. Whole exome sequencing of 10 treatment naïve tumour biopsies with matched blood samples, from a cohort of Indian patients with locally advanced disease, was performed. The data revealed missense mutations across 1282 genes, out of 1831 genes harbouring somatic mutations. These missense mutations (nonsynonymous + stop-gained) when compared with pre-existing mutations in the COSMIC database showed that 272 mutations in 250 genes were already reported although from cancers other than cervical cancer. More than 1000 novel somatic variations were obtained in matched tumour samples. Pathways / genes that are frequently mutated in various other cancers were found to be mutated in cervical cancers. A significant enrichment of somatic mutations in the MAPK pathway was observed, some of which could be potentially targetable. This is the first report of whole exome sequencing of well annotated cervical cancer samples from Indian women and helps identify trends in mutation profiles that are found in an Indian cohort of cervical cancer.


With 122800 new cases and 67400 deaths annually, cervical cancer significantly contributes to the cancer burden in India [1]. Although infection by HPV has been established as a major etiological factor for the genesis of the disease, only a small proportion of HPV infected women develop cervical cancer; [2]. This suggests possible involvement of genetic aberrations in development of cervical cancer. Over the years, studies have described direct role of various genetic alterations in disease development. Somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS as well as copy number alterations have been reported [25]. In addition, recurrent mutations in EP300, MAPKI, FBXW7, HLAB, NFE2L2 have been reported from a large study from Meyerson’s group [6].

Integration of HPV in the human genome could also contribute to genetic aberrations and alter gene expression, leading to cervical carcinogenesis. We and others have reported that the site of HPV integration is not totally random [7, 8]. Meyerson’s group has reported that gene expression levels at sites of HPV integration were higher in tumours with integration than level of expression in other tumours without integration at that site [6]. HPV integration may result in loss of function of tumour suppressors or critical DNA repair gene or gain of function of important oncogenes [9]. For instance, integration in the DNA repair gene RAD51B results in amplification of an intronic segment and expression of alternative RAD51B transcripts which are non-functional [10]. Similarly, integration in the tumor suppressor gene ETS2 is accompanied by deletion of exons at the integration site, resulting in truncated forms of the protein [10]. The integration process has also been reported to alter the copy number of potential oncogenes such as MYC, FOXE1, etc [9].

In the present study, we report the application of whole-exome sequencing technology for identifying trends in mutation profiles found in an Indian cohort of cervical cancer.

Materials and Methods

Clinical Samples

Ten pretreatment cervical tumour biopsies along with the matched blood samples from Indian patients with advanced stage cervical cancer (FIGO stage IIIB) were taken for the study. A generic consent for basic research was obtained prior to obtaining the biopsies. Since this was a retrospective study, patient informed consent for this particular project could not be obtained and permission for waiver from Institute Ethics Committee (IEC) was obtained. The study was approved by IEC. All procedures pertaining to sample collection and processing were in conformity with the IEC. The biopsies were obtained and stored in liquid Nitrogen as described earlier [8], from histologically proven, primary cervical tumour, before the start of radical radiation therapy. The samples were coded for identification by the physician prior to testing and were assigned a laboratory code to maintain confidentiality. Buffy coat was separated from blood samples by centrifugation.

Processing of tumour samples and isolation of genomic DNA

Cryosectioning of the cervical biopsies was done for hematoxylin-eosin (H&E) staining as well for isolation of DNA. The H&E stained sections were examined by the pathologist to assess the percentage of tumour in the sample. Samples with >70% tumour were taken for whole exome sequencing study. Genomic DNA was isolated from the tumour sections and buffy coat from matched blood samples, using DNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RNase treatment of the DNA samples was done using RNase A (Sigma, St. Louis, MO, USA).

Exome Capture and Next-Generation Sequencing

Matched tumour and blood samples from 10 cervical cancer patients were subjected to exome sequencing using Illumina platform. Exome capture and paired end sequencing of DNA was done using Paired-End Sample Preparation kit (Illumina, San Diego, CA, USA) followed by in-solution capture of genomic DNA using SureSelect Human All Exon kit (Agilent Technologies, Santa Clara CA, USA), targeting 37 Mb sequence from exons. For each sample, captured DNA was sequenced by multiplexed paired end sequencing using 2 pools of samples on Illumina GAIIx platform (Illumina, San Diego, CA, USA)

Bioinformatic analysis outline

The data were QC filtered and mapped to Human Genome version 37 (hg37.p13) using Bowtie. Variants were called using lofreq [11], which calls SNVs from each dataset (normal and tumour) and identifies somatic variations–including low frequency, rare alleles. The SNVs called by lofreq were subjected to quality filtering based on a) read depth for each variation; b) strand bias; c) end mapping bias; d) mapping quality; e) base RMS quality; and f) variant phred score. A given SNV was considered to be novel if it was not in the dbSNP nor in the 1000 genome database. The resultant variations were submitted to Variant Effect Predictor server ( and the effect of coding site variants identified. Further analyses were performed for the variations that resulted in a missense or nonsense mutation in coding regions (non-synonymous). The genes containing these SNVs were analyzed for their functional enrichment using GO classification (AMIGO2; These were also subjected to KEGG pathway analysis ( and compared to those previously reported in the COSMIC database (

Validation of the data by Sanger sequencing

A subset of variations was validated by PCR amplification of the region followed by Sanger sequencing of the amplicon. Primers were designed flanking the variation ~250 bp upstream and 250 bp downstream using NCBI primer Blast ( Standard PCR conditions were followed with the annealing temperature in the range between 55–65°C. The PCR products were purified using QIAquick PCR Purification kit (Qiagen, Hilden, Germany) and sequenced on DNA Sequencer (3100 Avant Genetic analyzer, Applied Biosystems, Foster City, CA, USA).


Clinical material

In the present study, 10 tumour biopsies along with matched blood from treatment naïve cervical cancers from a cohort of Indian women were included. The patients were in FIGO stage IIIB and their age ranged between 35–58 years. The HPV genotype and viral genome status in these patients was determined from an earlier study [8, 10]. Majority of the samples were positive for HPV16, although HPV18, 45 and 56 were also present [12]. In some of the samples, the virus was integrated in the genome [8]. The demographic details of the patients are given in Table 1.

Table 1. Demographic details of the 10 patients included in the whole exome sequencing study

Exome sequencing and somatic variations

The matched tumour and blood samples from 10 cervical cancer patients were subjected to exome sequencing using Illumina platform. On an average 97% of the reads could be mapped to the human genome (hg37.p13) and the average read depth was >20X. The matched blood control in each case was used to filter out the germline variations. Further quality filtering by methods as described in Materials and Methods, identified 2281 somatic variations falling within coding regions of which 1233 (54%) were of missense type, 68 (3%) stop gained, and the rest were synonymous coding and stop (retained) variations. The frequency of mutations in each of the 10 cases is shown in Fig 1. A total of 1831 genes were found to harbour somatic variations. A total of 299 genes carried at least 2 variations (either in same tumour or across tumours). A panel of 87 genes were found to be mutated in at least 2 tumours (Fig 2).

Fig 1. Frequency of somatic mutations in each of the 10 cases.

The frequency of all the mutations (synonymous and nonsynonymous) per Mb of genome is depicted. Each bar represents an individual tumour sample and the number below the bar is the designated laboratory number of each sample.

Fig 2. Heat map of frequently mutated genes.

A panel of 87 genes was found to be mutated in at least 2 tumour samples. Some of the genes had 3 mutations in the same sample.

Two genes, PDE4DIP (mutated in 4 tumours) and MUC16 (mutated in 2 tumours) carried 11 somatic variations each, making them the most mutated genes in the dataset. MUC17 showed a high frequency of mutations in a single sample. Apart from this, 80 ZNF family members representing 4.5% of the total number of genes harbouring somatic mutations were also found to be mutated. ZNF proteins had an overrepresentation in the list of somatically mutated genes, when compared to their overall frequency in the human genes (538 out of 32620 genes: 1.6%). This overrepresentation was statistically significant (Fisher’s p = 2.6 x 10–13; OR = 2.72; 95% CI = 2.11–3.47).

MAPK signal transduction pathway that is well known to play a key role in the pathogenesis of cancer, surfaced as one with most mutated genes in this dataset. KEGG lists 257 genes as part of the MAPK signal transduction pathway, including the core signal transduction cascade, the upstream ligands and other associated factors. Twelve of the 257 genes were identified to have somatic variations across patients. In order to assess the significance of this occurrence, we generated 1000 random gene sets of 257 each and calculated the frequency of observed somatic mutations in these sets; Z-scores were used as a measure of significance. The Z-score for finding 12 genes with somatic mutations out of 257 random genes was 2.69 (P-value = 0.004). This indicates a significant enrichment for somatic mutations in the MAPK pathway of these tumour samples

(Fig 3).

Fig 3. Randomization test for somatic mutations.

The curve represents the distribution of number of genes that belonged to the MAPK pathway in the 1000 sets of random genes. The mean of the data set is 5.7 somatic mutations in 257 genes with a standard deviation of 2.34. The red dot along the X-‐axis depicts a value of 12 –the number of MAPK genes having somatic mutations. The P-value was calculated based on the number of random sets that had less than 12 genes belonging to MAPK pathway. The number of somatic mutations observed in MAPK pathway is significantly higher than the mean (P = 0.0046).

Missense somatic variations from each paired tumour sample were used to analyze functional enrichment under the GO molecular function categories. All GO category enrichments with an adjusted p = 0.05 or less were considered to be significant. We did not find any negative enrichment (underrepresentation) of GO functional categories. In a combined GO analysis across multiple samples olfactory receptors, ion binding, signalling cascade receptor and signal transduction genes were found to be enriched.

Validation of selected variations by Sanger sequencing

A total of 53 somatic variations were randomly selected for variation by Sanger sequencing. Out of this, 25 were validated as true somatic and 10 turned out to be germline (Table 2).

Table 2. Variations from exome sequencing data validated by Sanger sequencing.

Comparison with COSMIC database

From the present dataset missense mutations were catalogued across 1282 genes, out of 1831 genes harbouring somatic mutations. These missense variations (nonsynonymous + stop-gained) were compared with pre-existing mutations in the COSMIC database. 272 mutations in 250 genes were common with those reported in COSMIC database (see S1 Table). However, the data did not match any known cervical cancer mutations.


Although HPV is the major causative factor for development of cervical cancer, the role of several genetic components in the disease has long been recognized. While allelic variation of HLA class II antigen [13, 14], and p53 codon 72 polymorphism [15] may increase the risk of developing the disease, mutations in Ras oncogene, PI3KA, STK11, are reported to directly cause or promote progression of cervical carcinoma [2, 3, 5]. Apart from this, a number of chromosomal aberrations have also been associated with the disease [4]. However, till date there are very few high throughput studies that describe the genetic landscape of the disease. The study by Ojesina et al. involving 100 Norwegian and 15 Mexican cervical carcinoma cases is the most significant among them. They identified recurrent mutations in MAPK, and mutations in genes such as HLA-B, EP300, FBXW7, NFE2L2,TP53 and ERBB2 in 79 primary squamous cell carcinomas and that of ELF3 and CBFB in 24 adenocarcinomas [6]. A study from Latin America reported mutations in PIK3CA to be a key player both in squamous and adeno cervical carcinomas [16]. Another study on cervical cancer cases of European origin identified PIK3CA, KRAS and FBXW7 to be the most mutated [17]. Chung et al have reported mutations in FAT1, ARID1A, ERBB2 and PIK3CA in 15 cervical adenocarcinomas cases of Chinese origin [18]. However, there are no reports on such studies on the Indian population. In the present study, using whole exome sequencing technology we have attempted to catalogue the somatic aberrations in a cohort of Indian cervical cancer cases. Initially identified as an effective tool for identification of a wide variety of novel variations especially in the field of Mendelian disorders [19], over past few years the technology has been quiet successful in discovering novel mutations in diseases characterized by marked genetic heterogeneity like cancer including the rare forms [20, 21].

Whole exome sequencing of 10 paired advanced stage cervical cancer biopsies from Indian cohort identified 1029 novel, non-synonymous variations. High frequency of mutations in two genes—PDE4DIP (a number of mutations in the same gene across samples) and MUC17 (a number of mutations in the same gene in only one sample) were found. Known for its role in anchoring phosphodiesterase 4D to the Golgi/centrosome region of the cell, deleterious mutations of PDE4DIP have recently been demonstrated to be involved in breast cancer [22].

A number of membrane-associated mucin genes such as MUC2, 4, 5B, 12, 16, 17, 20, 21 were found to be mutated in our dataset. Similar to our results, whole exome sequencing study of HPV negative versus HPV positive head and neck tumours identified MUC4, 12 and 16 as mutated [23]. We found MUC16 to be recurrently mutated across the samples. A number of MUC mutations have been reported in the COSMIC database for several cancer types. In general, the membrane associated mucins are also known to play role in invasion and metastasis by modulating the adhesive properties of cells [24]. On the other hand, it is possible that mutations in Muc16 as well as Muc4 are false positives as these are large genes which are low expressed and late replicating and therefore show a high frequency of mutations in the coding region [25].

An interesting finding from the present study was the overrepresentation of mutated members of the ZNF family. A total of 80 ZNF genes were found to be mutated. Zinc Finger members have been implicated in tumorigenesis and acquisition of resistance to drugs. Members of these family interact with nucleic acids, proteins and small molecules and are involved in a variety of crucial molecular processes in cells at replication, transcriptional and translational levels. Mutations of ZNF family members are associated with various diseases including cancer. Zinc Finger genes map to regions often deleted in solid tumours and involved in recurrent chromosomal rearrangements in hematological malignancies [26]. Deleterious mutation of one of the ZNF family members, PRDM1 has been associated with primary central nervous system lymphoma [27]. Corroborating our findings, a recent study has reported multiple mutations of the ZNF family genes in metastatic hepatocellular carcinoma. [28]. As reported in the study by Nicholas et. al., for HPV positive and negative head and neck squamous cancer, ZNF family members including ZNF10, ZNF470 and ZNF716 were also found to be mutated in our dataset [23]

GO analysis identified a large number of olfactory receptor gene mutations. Mutations in olfactory receptors are now being associated with cancer [29] [30], tumour invasion and metastasis [31]. However, according to a recent report, high frequency of somatic mutations in these genes may be red herrings during high throughput sequencing of cancer genomes. According to this study, genes such as the olfactory receptors that have low expression, are late in replicating and display a high regional noncoding mutation rate, are more prone to somatic mutations in their coding regions and hence are seen in many cancer genomics data [25]. Therefore, in order to conclude whether mutations in these receptors play any role in cervical carcinogenesis, more samples need to be sequenced as well as functional analysis of these genes in cell lines and patient samples is required.

Of the mutations that have occurred in single samples and have been identified and validated from the dataset, there were several significant candidates known for their role in the process of tumorigenesis. For instance FGF7 is known for its mitogenic and cell survival activities [32]; MAP3K3 is involved in direct activation of stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways [33] as well as plays a critical role in TNF-induced NF-kappaB activation [34]. RASA1 helps in control of cellular proliferation and its mutation is associated with basal cell carcinoma [35]. RNF111 acts as a tumour suppressor in preventing development and progression of colorectal cancer [36]. CDCA7L interacts with c-Myc in bringing about cellular transformation in medulloblastoma [37]. Mutation of CD274 leading to its overexpression have been associated with gastric carcinoma [38]. Apart from these, mutations in ODZ1, TTN and EP300 are already reported in cervical cancer. The variation in the transcriptional regulator, EP300 (D1399N) was identical to that reported in COSMIC database. EP300 was also reported to be one of the genes with significant recurrent somatic mutations in the study by Ojesina et al [6].

Despite the important role played by each of these genes, majority of the mutations would be ‘passengers’ and identifying potential ‘drivers’ with a cardinal role in cervical carcinogenesis from this data would be the actual challenge. Several methods have been described that can predict potential driver mutations in a cancer genome [39, 40]. These, combined with functional characterization of the variants and validation studies involving larger sample size might help in identifying potential ‘drivers’ in cervical carcinogenesis.

A significant proportion of the genes found to be mutated such as MAP3K3, SOS2, FGF7, TGFBR2, TRAF2, RASA1 and RPS6KA6 belong to the MAPKinase signal transduction pathway that is known to play a significant role in cell proliferation and apoptosis. This observation is in concordance with the study by Ojesina et al [6]. This indicates that the MAPKinase pathway is one of the highly mutated pathways in cervical carcinogenesis and hence might be more vulnerable to therapeutic intervention.

The major highlight of our study was to identify non-synonymous, somatic variations (mutations) that might play a potential role in cervical carcinogenesis. We could not find any significant driver mutation that could lead to cervical carcinogenesis. This might be due to the fact that all (except one) of the samples were positive for high risk HPV which are known to target the two key cell cycle regulators-p53 and Rb for proteasomal degradation, without incurring mutation. In our study, HPV infection in the samples and its integration was determined by Luminex Bead Array [8]. Presence of HPV and its integration status was also confirmed in the exome sequencing data of the samples [12]. Thus, our treatment naïve primary cancers could be HPV driven and hence no driver mutations are seen.

Our results suggest that there is considerable genetic and mechanistic heterogeneity in cervical cancers. Pathways / genes that are frequently mutated in various other cancers are also mutated in cervical cancers indicating that specific mutational signatures notwithstanding, distinct cancers based on their tissue of origin, are offshoots of the same mechanistic process. Thus, a tumour driving pathway in prostrate or lung cancer may well be the culprit even in cervical cancer. Given this convergence of pathways / mechanisms across cancer types, one can explore the possibility of cross-treating cancers, for example, the same drug may be effective against two divergent cancer types if they carry the same mutational signature at the pathway level.

To the best of our knowledge, this is the first study where whole exome sequencing has been applied to understanding the mutational landscape of the disease in an Indian cohort. However, there might be several polymorphisms that predispose an individual to the disease or aid the HPV in causing cervical cancer, which we have not dealt with in this study. An additional aspect of the study is that it provides an insight into the genome of Indian individuals by identifying a number of novel variations which could enrich the existing databases.

Supporting Information

S1 Table. List of somatic mutations in common with COSMIC database




The authors thank all individuals from the Gynaecology Disease Management Group, Tata Memorial Hospital, Mumbai who were involved in judiciously collecting, storing the biopsies from cervical cancer patients and compiling the clinical history.

Author Contributions

  1. Conceptualization: RM PD.
  2. Data curation: RM.
  3. Formal analysis: KS.
  4. Funding acquisition: RM.
  5. Investigation: RM PD AB UM SKS KD.
  6. Methodology: PD AB UM SKS KD SNR.
  7. Project administration: RM.
  8. Resources: SNR RM.
  9. Software: SNR KS.
  10. Supervision: RM.
  11. Validation: PD AB.
  12. Visualization: RM PD KS.
  13. Writing – original draft: PD.
  14. Writing – review & editing: RM PD KS UM.


  1. 1. GLOBOCAN 2012 (IARC) Section of Cancer Surveillance (17/12/2015). 2015.
  2. 2. Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin KL. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol. 2009 Feb;34(2):409–16. pmid:19148475
  3. 3. Wong YF, Chung TK, Cheung TH, Lam SK, Xu YG, Chang AM. Frequent ras gene mutations in squamous cell cervical cancer. Cancer Lett. 1995 Aug 16;95(1–2):29–32. pmid:7656240
  4. 4. Narayan G, Murty VV. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol. 2010 Oct;6(10):1643–52. doi: 10.2217/fon.10.114. pmid:21062161
  5. 5. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One. 2009;4(4):e5137. doi: 10.1371/journal.pone.0005137. pmid:19340305
  6. 6. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20;506(7488):371–5. doi: 10.1038/nature12881. pmid:24390348
  7. 7. Christiansen IK, Sandve GK, Schmitz M, Durst M, Hovig E. Transcriptionally active regions are the preferred targets for chromosomal HPV integration in cervical carcinogenesis. PLoS One. 2015;10(3):e0119566. doi: 10.1371/journal.pone.0119566. pmid:25793388
  8. 8. Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K, Mulherkar R. HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One. 2012;7(7):e41012. doi: 10.1371/journal.pone.0041012. pmid:22815898
  9. 9. Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res. 2015 May 1;21(9):2009–19. doi: 10.1158/1078-0432.CCR-14-1101. pmid:25779941
  10. 10. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544–9. doi: 10.1073/pnas.1416074111. pmid:25313082
  11. 11. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012 Dec;40(22):11189–201. doi: 10.1093/nar/gks918. pmid:23066108
  12. 12. Chandrani P, Kulkarni V, Iyer P, Upadhyay P, Chaubal R, Das P, et al. NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome. Br J Cancer. 2015 Jun 9;112(12):1958–65. doi: 10.1038/bjc.2015.121. pmid:25973533
  13. 13. Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1035–41. pmid:9829713
  14. 14. Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, Smith AG, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis. 2002 Dec 1;186(11):1565–74. doi: 10.1086/345285. pmid:12447731
  15. 15. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. [Research Support, Non-U.S. Gov't]. 1998 May 21;393(6682):229–34. doi: 10.1038/30400. pmid:9607760
  16. 16. Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, et al. Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res. 2015 Dec 1;21(23):5360–70. doi: 10.1158/1078-0432.CCR-14-1837. pmid:26080840
  17. 17. Muller E, Brault B, Holmes A, Legros A, Jeannot E, Campitelli M, et al. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. Cancer Med. 2015 Oct;4(10):1484–93. doi: 10.1002/cam4.492. pmid:26155992
  18. 18. Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, et al. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Jan 27.
  19. 19. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011 Nov;12(11):745–55. doi: 10.1038/nrg3031. pmid:21946919
  20. 20. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010 Dec 3;330(6009):1410–3. doi: 10.1126/science.1194472. pmid:21051595
  21. 21. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Oct 6;478(7367):64–9. doi: 10.1038/nature10496. pmid:21909114
  22. 22. Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, et al. Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013;3:2256. doi: 10.1038/srep02256. pmid:23884293
  23. 23. Nichols AC, Chan-Seng-Yue M, Yoo J, Xu W, Dhaliwal S, Basmaji J, et al. A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. ISRN Oncol. 2012;2012:809370. doi: 10.5402/2012/809370. pmid:23304554
  24. 24. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci. 1992 Sep;17(9):359–63. pmid:1412714
  25. 25. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11;499(7457):214–8. doi: 10.1038/nature12213. pmid:23770567
  26. 26. Tommerup N, Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics. 1995 May 20;27(2):259–64. doi: 10.1006/geno.1995.1040. pmid:7557990
  27. 27. Courts C, Montesinos-Rongen M, Brunn A, Bug S, Siemer D, Hans V, et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol. 2008 Jul;67(7):720–7. doi: 10.1097/NEN.0b013e31817dd02d. pmid:18596541
  28. 28. Ouyang L, Lee J, Park CK, Mao M, Shi Y, Gong Z, et al. Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas. BMC Med Genomics. 2014;7:2. doi: 10.1186/1755-8794-7-2. pmid:24405831
  29. 29. Xu L, Tang H, Chen DW, El-Naggar AK, Wei P, Sturgis EM. Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes. Cancer. 2015 Jul 15;121(14):2367–74. doi: 10.1002/cncr.29381. pmid:25823930
  30. 30. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807–12. doi: 10.1126/science.1164382. pmid:18772396
  31. 31. Sanz G, Leray I, Dewaele A, Sobilo J, Lerondel S, Bouet S, et al. Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation. PLoS One. 2014;9(1):e85110. doi: 10.1371/journal.pone.0085110. pmid:24416348
  32. 32. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 Jun 21;271(25):15292–7. pmid:8663044
  33. 33. Ellinger-Ziegelbauer H, Brown K, Kelly K, Siebenlist U. Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem. 1997 Jan 31;272(5):2668–74. pmid:9006902
  34. 34. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol. 2001 Jul;2(7):620–4. doi: 10.1038/89769. pmid:11429546
  35. 35. Friedman E, Gejman PV, Martin GA, McCormick F. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nat Genet. 1993 Nov;5(3):242–7. doi: 10.1038/ng1193-242. pmid:8275088
  36. 36. Sharma V, Antonacopoulou AG, Tanaka S, Panoutsopoulos AA, Bravou V, Kalofonos HP, et al. Enhancement of TGF-beta signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer. Cancer Res. 2011 Oct 15;71(20):6438–49. doi: 10.1158/0008-5472.CAN-11-1645. pmid:21998011
  37. 37. Huang A, Ho CS, Ponzielli R, Barsyte-Lovejoy D, Bouffet E, Picard D, et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res. 2005 Jul 1;65(13):5607–19. doi: 10.1158/0008-5472.CAN-05-0500. pmid:15994933
  38. 38. Wang W, Sun J, Li F, Li R, Gu Y, Liu C, et al. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat. 2012 Mar;33(3):480–4. doi: 10.1002/humu.22014. pmid:22190470
  39. 39. Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer Res. 2008 Mar 15;68(6):1675–82. doi: 10.1158/0008-5472.CAN-07-5283. pmid:18339846
  40. 40. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268–74. doi: 10.1126/science.1133427. pmid:16959974